image
Figure 2: Safety profile of grass allergy immunotherapy tablet in all patients treated during the entire observation period. Data are the percentages of pediatric patients (<18 years) and adults (≥ 18 years) with adverse drug reactions (ADRs) observed in ≥ 1 % of patients (MedDRA preferred terms).
Goto home»